MORPHEUS-panBC: what clinicians are saying
atezolizumab plus tocilizumab; atezolizumab plus sacituzumab govitecan; atezolizumab plus ipatasertib in metastatic breast cancer · NCT03424005 ↗ · Phase 1/Phase 2 · Hoffmann-La Roche
Speakers viewed MORPHEUS-panBC favorably for early activity, although one cautioned that the interim patient group was small and survival data were not yet mature. One speaker looked ahead to pembrolizumab data and a possible change in practice. The statements provide no safety interpretation or evidence that routine care changed.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 7 verified statements
3 findings, and what sits behind each
01. MORPHEUS: speakers note activity; one flags small n, immature survival
No named clinician · accounts and unnamed speakers · 4 statements from 4 speakers in 3 sources · 4 passages
Limitations recorded: 2.
Draws on: Population and setting, Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, The comparison, Design and conduct.
02. MORPHEUS: a speaker relays apparent benefit but flags short follow-up
No named clinician · accounts and unnamed speakers · 2 statements from 1 speaker in 1 source, a podcast or video · 1 passage
Limitations recorded: 1.
Draws on: Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, The comparison, Design and conduct.
Beyond the trial population
03. Pembrolizumab: a speaker looks ahead to data and possible practice change
No named clinician · accounts and unnamed speakers · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 3
No named clinician · accounts and unnamed speakers
MORPHEUS: speakers note activity; one flags small n, immature survival
4 statements from 4 speakers in 3 sources
4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “one flags small n, immature survival”
- 4
- statements
- 4
- passages
- 3
- sources
- 4
- speakers
What the statements areViews 4Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 4Giving context 1Recorded with the findingLimitations: 2
3 posts and articles
Draws on: Population and setting, Primary endpoint: Objective Response Rate (ORR), Secondary endpoints, The comparison, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 3 findings and 1 of the 7 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (4)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate.
The full MORPHEUS-panBC report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 12commentary sources screened
- 4sources cited by verified statements
- 5named in screened sources
- 5speakers cited in the report
- 4cited speakers with a verified identity
0 cited clinicians, speakers with a confirmed clinical role, of them 0 physicians.
- 7verified statements, each linked to its source
- 0of them from speakers with a confirmed clinical role
- 3findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 7 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 0 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 8 | Free |
| Sources with links | 4 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
7 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Objective Response Rate (ORR) | 2 | 2 |
| Secondary endpoints | 2 | 2 |
| Population and setting | 2 | 2 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 2 | 2 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conduct | 2 | 2 |
| Presentation salience and brief favorable reactions | 2 | 2 |
| Future pembrolizumab data and possible practice change | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
7 verified statements from 4 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 2 statements · 29% | ||||
| YouTube | 2 | 1 | 1 | |
| Posts · 5 statements · 71% | ||||
| X threads | 5 | 3 | 11 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 7 / quarter
- Screened window
- May 11, 2023 → Oct 25, 2026
- Cited window
- May 15, 2024 → May 20, 2024
- Retrieved
- Nov 20, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
- Registry
- NCT03424005
- Study IDs
- CO40115 · 2017-002038-21 · 2023-503629-20-00
- Sponsor
- Hoffmann-La Roche
- Collaborators
- Gilead Sciences, Pfizer
- Design
- Phase 1/Phase 2 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 1,132 estimated
- Registered
- 2018-02-06
- Start
- 2018-03-30 actual
- Primary completion
- 2030-09-30 estimated
- Primary endpoint
- Objective Response Rate (ORR)
- Interventions
- 23 registered
More on: Breast cancer, atezolizumab, ipatasertib, tocilizumab, sacituzumab govitecan
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 7 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 51 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion; reposts do not add independent clinical assessments.
- Searches emphasized trial identifiers and names, so discussion using unnamed references or other variants may be missing.
Show all 8 known gaps +Fewer −
- The favorable interpretations were qualified by a small interim patient group, immature survival and short follow-up; they should not be read as mature benefit–risk conclusions.
- No numerical comparative endpoint estimates, safety or tolerability interpretation, or documented change in routine care appears in the cited statements.
- No protocol was listed in the registry, and no publication for the exact trial was identified for this edition. This report describes public interpretations rather than an independent assessment of a full trial report.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. MORPHEUS-panBC (NCT03424005): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/morpheus-panbc-nct03424005
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "MORPHEUS-panBC" (NCT03424005), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "morpheus-panbc-nct03424005". If you cannot make requests, read https://www.erudio.com/reports/morpheus-panbc-nct03424005.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT03424005", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT03424005 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/morpheus-panbc-nct03424005.json
curl https://www.erudio.com/reports/morpheus-panbc-nct03424005.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "morpheus-panbc-nct03424005" })release 61b5095726d401d7aa480bfe00afea217559ef121cea566f92cb746e12df277c
Questions
How much does the MORPHEUS-panBC report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the MORPHEUS-panBC report cover?
7 statements from 4 sources (1 video, 3 posts), each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the MORPHEUS-panBC report?
Its preview, yes: get_report_card({ "slug": "morpheus-panbc-nct03424005" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the MORPHEUS-panBC report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.